Brouwer Roald
Known title: Chief Technology OfficerCIK: 0002069148
Brouwer Roald's purchase track record
How the stock did after each of Brouwer Roald's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 6 since August 8, 2025
Stock higher 6 months later
75%
3 months: 40%
Median 6-month return
+12.9%
3 months: -3.4%
Beat the S&P 500
50%
median +6.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/11/2026 | AMRZ | $70K | pending | pending | — |
| 5/21/2026 | AMRZ | $75K | -11.6% | pending | — |
| 3/11/2026 | AMRZ | $286K | -12.4% | -28.9% | +12.7% |
| 10/31/2025 | AMRZ | $207K | +1.5% | +3.8% | +5.7% |
| 8/27/2025 | AMRZ | $104K | -3.4% | +22.0% | +7.2% |
| 8/8/2025 | AMRZ | $141K | +3.7% | +22.5% | +8.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AMRZ | ▲ Buy | Open Market | 1,500 | $70K | 8/11/2026 | View on chart |
| AMRZ | ▲ Buy | Grant | 233 | $11K | 6/30/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,500 | $75K | 5/21/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 2,000 | $110K | 3/13/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 3,000 | $176K | 3/11/2026 | View on chart |
| AMRZ | ▲ Buy | Grant | 4,257 | $0 | 2/27/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 3,000 | $155K | 10/31/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,000 | $52K | 10/31/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 2,000 | $104K | 8/27/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,000 | $47K | 8/12/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 218 | $10K | 8/11/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 782 | $38K | 8/11/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,000 | $46K | 8/8/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JP Morgan cuts Amrize price target to $48, maintains Neutral
JP Morgan has lowered its price target for Amrize to $48 while keeping a Neutral rating. This move comes as the company prepares to announce its third-quarter 2026 financial results. Recent reports also highlight the firm's regional scale and pricing power, though the current analyst target sits below the average consensus of $47.20.
JP Morgan cuts Amrize price target to $48, maintains Neutral. JP Morgan has lowered its price target for Amrize to $48 while keeping a Neutral rating. This move comes as the company prepares to announce its third-quarter 2026 financial results. Recent reports also highlight the firm's regional scale and pricing power, though the current analyst target sits below the average consensus of $47.20.